背景:局部晚期胰腺癌(LAPC),不受控制的局部肿瘤生长经常导致死亡。放射治疗(RT)技术的进步已经实现了剂量递增RT(EDR)的适形递送,根据回顾性和早期前瞻性研究,这可能具有潜在的局部控制和总体生存(OS)益处。随着EDR证据的出现,我们对整个美国采用EDR及其相关结果进行了描述。
方法:我们检索了国家癌症数据库中2004年至2019年间诊断为非手术治疗的LAPC患者。具有生物学有效剂量(BED10)≥39且≤70Gy的胰腺定向RT标记为常规剂量RT(CDR),BED10>70且≤132Gy标记为EDR。我们使用logistic和Cox回归确定了EDR和OS的关联,分别。
结果:在整个研究队列(n=91,493)的确定治疗子集(n=54,115)中,最常见的治疗方法是单纯化疗(69%),化疗和放疗(29%),和RT单独(2%)。对于放射治疗子集(n=16,978),在研究期间,胰腺定向RT的使用保持在13%~17%之间(ptrend>0.999).使用多变量逻辑回归,在学术/研究机构的治疗(调整后的比值比[aOR]1.46,p<0.001)和2016年至2019年的治疗(aOR2.54,p<0.001)与更多的EDR接收相关,而使用化疗(aOR为0.60,p<0.001)与较少的接收相关.EDR和CDR的中位OS估计为14.5个月和13.0个月(p<0.0001),分别。对于具有可用生存数据的放射治疗子集患者(n=13,579),多变量Cox回归将EDR(校正风险比0.85,95%置信区间0.80-0.91;p<0.001)与较长的OS相对于CDR相关。
结论:自2016年以来,EDR的利用率有所增加,但LAPC的RT的总体利用率在近20年来一直保持在不到五分之一的患者。这些真实世界的结果还为未来的前瞻性试验提供了EDR效应大小的估计。
BACKGROUND: With locally advanced pancreatic cancer (LAPC), uncontrolled local tumor growth frequently leads to mortality. Advancements in radiotherapy (RT) techniques have enabled conformal delivery of escalated-dose RT (EDR), which may have potential local control and overall survival (OS) benefits based on retrospective and early prospective studies. With evidence for EDR emerging, we characterized the adoption of EDR across the United States and its associated outcomes.
METHODS: We searched the National Cancer Database for nonsurgically managed LAPC patients diagnosed between 2004 and 2019. Pancreas-directed RT with biologically effective doses (BED10) ≥39 and ≤70 Gy was labeled conventional-dose RT (CDR), and BED10 >70 and ≤132 Gy was labeled EDR. We identified associations of EDR and OS using logistic and Cox regressions, respectively.
RESULTS: Among the definitive therapy subset (n = 54,115) of the entire study cohort (n = 91,493), the most common treatments were chemotherapy alone (69%), chemotherapy and radiation (29%), and RT alone (2%). For the radiation therapy subset (n = 16,978), use of pancreas-directed RT remained between 13% and 17% over the study period (ptrend > 0.999). Using multivariable logistic regression, treatment at an academic/research facility (adjusted odds ratio [aOR] 1.46, p < 0.001) and treatment between 2016 and 2019 (aOR 2.54, p < 0.001) were associated with greater receipt of EDR, whereas use of chemotherapy (aOR 0.60, p < 0.001) was associated with less receipt. Median OS estimates for EDR and CDR were 14.5 months and 13.0 months (p < 0.0001), respectively. For radiation therapy subset patients with available survival data (n = 13,579), multivariable Cox regression correlated EDR (adjusted hazard ratio 0.85, 95% confidence interval 0.80-0.91; p < 0.001) with longer OS versus CDR.
CONCLUSIONS: Utilization of EDR has increased since 2016, but overall utilization of RT for LAPC has remained at less than one in five patients for almost two decades. These real-world results additionally provide an estimate of effect size of EDR for future prospective trials.